714-P: Assessment of the Patient Transition Experience to Hybrid Closed-Loop Insulin Pump Therapy

• DOI: 10.2337/db21-714-p
• Publication Date: 2021-06-24T22:15:10Z
• Authors: ASHINI DISSANAYAKE; ERIC CHOW; ADAM WHITE; JORDANNA E. KAPELUTO; JESSICA MACKENZIE...; BENJAMIN SCHROEDER; MONIKA PAWLOWSKA
• Keywords: Insulin pump

Hybrid closed-loop (HCL) insulin pump therapy is a promising development for the management of type 1 diabetes (T1D), but little known about transition period to HCL in real-world setting. Here, we present novel data evaluating experience and its effect on distress. We evaluated 32 out 150 anticipated participants who were (Arm A), or had recently transitioned B), from standard MiniMed™ 670G pump. Patients completed baseline 6-month post-transition distress survey using T1-DDS. In follow-up survey, patients’ trust treatment satisfaction also assessed. Finally, post-survey interviews conducted patients elaborate successes struggles their experience. No significant differences observed between 2 arms, so sample was analyzed as whole. After 6 months HCL, reductions overall (p<0.0001), well powerlessness (p<0.005), (p<0.001), hypoglycemia eating (p<0.0005) Most (56%) indicated difficulty trusting however 80% reported that improved over time. Patient high (81%), only 47% met expectations, 56% would recommend others, 66% frustration with HCL. divided whether increased (41%) decreased (47%) workload required manage T1D (12% neutral). Over half (59%) felt too complicated. much “hassle” use (31% yes, 38% no, 31% Emerging themes qualitative include numerous alarms, loss sleep, necessity “phantom carbing.” Overall, significantly reduces distress, patient varied terms trust, satisfaction, comfort technology. Disclosure A. Dissanayake: None. E. Chow: White: Advisory Panel; Self; Abbott Diabetes, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly Company, Janssen Pharmaceuticals, Inc., Merck & Co., Novo Nordisk Canada Inc. J. Kapeluto: Mackenzie-feder: B. Schroeder: Novartis Pharmaceuticals M. Pawlowska: Nordisk.